Literature DB >> 10713704

Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line.

S C Rosa Santos1, S Dumon, P Mayeux, S Gisselbrecht, F Gouilleux.   

Abstract

Cytokine-dependent activation of distinct signaling pathways is a common scheme thought to be required for the subsequent programmation into cell proliferation and survival. The PI 3-kinase/Akt, Ras/MAP kinase, Ras/NFIL3 and JAK/STAT pathways have been shown to participate in cytokine mediated suppression of apoptosis in various cell types. However the relative importance of these signaling pathways seems to depend on the cellular context. In several cases, individual inhibition of each pathway is not sufficient to completely abrogate cytokine mediated cell survival suggesting that cooperation between these pathways is required. Here we showed that individual inhibition of STAT5, PI 3-kinase or MEK activities did not or weakly affected the IL-3 dependent survival of the bone marrow derived Ba/F3 cell line. However, the simultaneous inhibition of STAT5 and PI 3-kinase activities but not that of STAT5 and MEK reduced the IL-3 dependent survival of Ba/F3. Analysis of the expression of the Bcl-2 members indicated that phosphorylation of Bad and Bcl-x expression which are respectively regulated by the PI 3-kinase/Akt pathway and STAT5 probably explain this cooperation. Furthermore, we showed by co-immunoprecipitation studies and pull down experiments with fusion proteins encoding the GST-SH2 domains of p85 that STAT5 in its phosphorylated form interacts with the p85 subunit of the PI 3-kinase. These results indicate that the activations of STAT5 and the PI 3-kinase by IL-3 in Ba/F3 cells are tightly connected and cooperate to mediate IL-3-dependent suppression of apoptosis by modulating Bad phosphorylation and Bcl-x expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713704     DOI: 10.1038/sj.onc.1203418

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter.

Authors:  Rémy Nyga; Christian Pecquet; Noria Harir; Haihua Gu; Isabelle Dhennin-Duthille; Aline Régnier; Valérie Gouilleux-Gruart; Kaïss Lassoued; Fabrice Gouilleux
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

Review 2.  Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.

Authors:  Patrick D Rädler; Barbara L Wehde; Kay-Uwe Wagner
Journal:  Mol Cell Endocrinol       Date:  2017-05-08       Impact factor: 4.102

3.  Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.

Authors:  G W Reuther; Q T Lambert; M A Caligiuri; C J Der
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

4.  The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction.

Authors:  Isabelle Dhennin-Duthille; Rémy Nyga; Saliha Yahiaoui; Valérie Gouilleux-Gruart; Aline Régnier; Kaïss Lassoued; Fabrice Gouilleux
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

5.  Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia.

Authors:  Feng Zhang; Suping Wang; Guodong Cao; Yanqin Gao; Jun Chen
Journal:  Neurobiol Dis       Date:  2006-09-27       Impact factor: 5.996

6.  Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients.

Authors:  Chun Fu Zheng; Gareth J Jones; Meiqing Shi; Jeremy C D Wiseman; Kaleb J Marr; Byron M Berenger; Shaunna M Huston; M John Gill; Alan M Krensky; Paul Kubes; Christopher H Mody
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

7.  Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies.

Authors:  S Kasper; F Breitenbuecher; F Heidel; S Hoffarth; B Markova; M Schuler; T Fischer
Journal:  Blood Cancer J       Date:  2012-03-09       Impact factor: 11.037

8.  Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin.

Authors:  G Li; K L Miskimen; Z Wang; X Y Xie; W Tse; F Gouilleux; R Moriggl; K D Bunting
Journal:  Leukemia       Date:  2010-06-10       Impact factor: 11.528

9.  Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.

Authors:  Dirk Fahrenkamp; Hildegard Schmitz-Van de Leur; Andrea Küster; Nicolas Chatain; Gerhard Müller-Newen
Journal:  Cell Commun Signal       Date:  2015-02-15       Impact factor: 5.712

Review 10.  STAT5-Interacting Proteins: A Synopsis of Proteins that Regulate STAT5 Activity.

Authors:  Ashley A Able; Jasmine A Burrell; Jacqueline M Stephens
Journal:  Biology (Basel)       Date:  2017-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.